Tag: Progenics Pharmaceuticals
June 13, 2019
Progenics Pharmaceuticals Doses First Patient in Phase 2 Clinical Study of 1095 Radiotherapy
Progenics Pharmaceuticals (NASDAQ:PGNX) has announced the first patient in its Phase 2 clinical trial studying I-131 1095 radiotherapy has been... May 14, 2019
Progenics Pharmaceuticals and ROTOP Pharmaka GmbH Announce European Collaboration
Progenics Pharmaceuticals (NASDAQ:PGNX) has announced an exclusive agreement with ROTOP Pharmaka GmbH to develop and commercialize Progenics’ 1404 prostate specific... February 11, 2019
Progenics Acquires AZEDRA® (iobenguane I 131) Radiopharmaceutical Manufacturing Facility
Progenics Pharmaceuticals (NASDAQ:PGNX) has announced it has acquired a manufacturing facility for AZEDRA for cash consideration of US$8 million. AZEDRA...
October 15, 2018
Biotech Update: Q3 2018 in Review
With the first three quarters of 2018 over, the Investing News Network is reviewing top news in the biotech space... October 5, 2018
Progenics Reports Results of Phase 2/3 Trial of PSMA PET Imaging Agent PyL for the Detection of Prostate Cancer
Progenics Pharmaceuticals (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced...
July 31, 2018